{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T16:51:38Z","timestamp":1786380698657,"version":"build-2736575974"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,9]]},"DOI":"10.7759\/cureus.14387","type":"journal-article","created":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T17:47:04Z","timestamp":1617990424000},"source":"Crossref","is-referenced-by-count":5,"title":["Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma"],"prefix":"10.7759","author":[{"given":"Rachel","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamish","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.2233","article-title":"Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade","volume":"151","author":"Sheik Ali S","year":"2015","unstructured":"Sheik Ali S, Goddard AL, Luke JJ, Donahue H, Todd DJ, Werchniak A, Vleugels RA. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol. 2015, 151:195-9. 10.1001\/jamadermatol.2014.2233","journal-title":"JAMA Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2018.01.030","article-title":"Nivolumab-induced myositis: a case report and a literature review","volume":"387","author":"Bourgeois-Vionnet J","year":"2018","unstructured":"Bourgeois-Vionnet J, Joubert B, Bernard E, et al.. Nivolumab-induced myositis: a case report and a literature review. J Neurol Sci. 2018, 387:51-3. 10.1016\/j.jns.2018.01.030","journal-title":"J Neurol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.05.006","article-title":"Myositis as an adverse event of immune checkpoint blockade for cancer therapy","volume":"48","author":"Shah M","year":"2019","unstructured":"Shah M, Tayar JH, Abdel-Wahab N, Suarez-Almazor ME. Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Semin Arthritis Rheum. 2019, 48:736-40. 10.1016\/j.semarthrit.2018.05.006","journal-title":"Semin Arthritis Rheum"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000118","article-title":"Successful anti-PD-1 antibody treatment in a metastatic melanoma patient with known severe autoimmune disease","volume":"39","author":"Maul LV","year":"2016","unstructured":"Maul LV, Weichenthal M, K\u00e4hler KC, Hauschild A. Successful anti-PD-1 antibody treatment in a metastatic melanoma patient with known severe autoimmune disease. J Immunother. 2016, 39:188-90. 10.1097\/CJI.0000000000000118","journal-title":"J Immunother"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar M","year":"2018","unstructured":"Lidar M, Giat E, Garelick D, et al.. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev. 2018, 17:284-9. 10.1016\/j.autrev.2018.01.003","journal-title":"Autoimmun Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/art.40745","article-title":"Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients","volume":"71","author":"Richter MD","year":"2019","unstructured":"Richter MD, Crowson C, Kottschade LA, Finnes HD, Markovic SN, Thanarajasingam U. Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients. Arthritis Rheumatol. 2019, 71:468-75. 10.1002\/art.40745","journal-title":"Arthritis Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab N","year":"2018","unstructured":"Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med. 2018, 168:121-30. 10.7326\/M17-2073","journal-title":"Ann Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7326\/M20-3419","article-title":"Safety and efficacy of checkpoint inhibition in patients with melanoma and preexisting autoimmune disease: a cohort study [Online ahead of print]","author":"van der Kooij MK","year":"2021","unstructured":"van der Kooij MK, Suijkerbuijk KPM, Aarts MJB, et al.. Safety and efficacy of checkpoint inhibition in patients with melanoma and preexisting autoimmune disease: a cohort study [Online ahead of print]. Ann Intern Med. 2021, 10.7326\/M20-3419","journal-title":"Ann Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000412","article-title":"Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity","volume":"3","author":"Calabrese C","year":"2017","unstructured":"Calabrese C, Kirchner E, Kontzias A, Velcheti V, Calabrese LH. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open. 2017, 3:000412. 10.1136\/rmdopen-2016-000412","journal-title":"RMD Open"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.05.002","article-title":"Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: fasciitis with myositis syndrome as a new complication of immunotherapy","volume":"17","author":"Narv\u00e1ez J","year":"2018","unstructured":"Narv\u00e1ez J, Juarez-L\u00f3pez P, LLuch J, et al.. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: fasciitis with myositis syndrome as a new complication of immunotherapy. Autoimmun Rev. 2018, 17:1040-5. 10.1016\/j.autrev.2018.05.002","journal-title":"Autoimmun Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.035898","article-title":"Immune checkpoint inhibitor-associated myositis: expanding the spectrum of cardiac complications of the immunotherapy revolution","volume":"138","author":"Anquetil C","year":"2018","unstructured":"Anquetil C, Salem JE, Lebrun-Vignes B, et al.. Immune checkpoint inhibitor-associated myositis: expanding the spectrum of cardiac complications of the immunotherapy revolution. Circulation. 2018, 138:743-5. 10.1161\/CIRCULATIONAHA.118.035898","journal-title":"Circulation"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/54310-dermatomyositis-flare-with-immune-checkpoint-inhibitor-therapy-for-melanoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:27:11Z","timestamp":1707506831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/54310-dermatomyositis-flare-with-immune-checkpoint-inhibitor-therapy-for-melanoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,9]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.14387","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,9]]}}}